Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454341 | 1.00 | LMNA (0.38) | LMNAGAAMAPT | |
| SCHEMBL8574244 | 1.00 | LMNA (0.38) | LMNAGAAMAPT | |
| Hydrochloric Acid SCHEMBL8478125 | 0.98 | LMNA (0.37) | LMNAGAAMAPT | |
| SCHEMBL8569731 | 0.89 | LMNA (0.31) | LMNAGAAMAPT | |
| SCHEMBL9815219 | 0.89 | LMNA (0.31) | LMNAGAAMAPT | |
| SCHEMBL10333301 | 0.86 | — | — | |
| SCHEMBL9199085 | 0.86 | — | — | |
| SCHEMBL3710407 | 0.86 | LMNA (0.32) | LMNAGAAMAPT | |
| SCHEMBL2456035 | 0.86 | LMNA (0.32) | LMNAGAAMAPT | |
| SCHEMBL3710405 | 0.86 | LMNA (0.32) | LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112295741-B | Test method for recovering and concentrating sulfide ore | 江西浒坑钨业有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-112295741-A | Test method for recovering and concentrating sulfide ore | 江西浒坑钨业有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-111606869-A | Protection method for carboxyl of ceftobiprole active thioester intermediate | 山西千岫制药有限公司 | 2020-09-01 | — | — | CN | claimed |
| CN-103570749-A | Cefozopran preparation technology | ANHUI YOUCARE KAIYUE PHARMACEUTICAL CO LTD | 2014-02-12 | — | — | CN | claimed |
| WO-2010089729-A1 | PROCESSES FOR THE PREPARATION OF CEFOZOPRAN, ITS SALTS AND POLYMORPHIC FORMS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| US-4585872-A | CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | claimed |
| CN-112295741-B | Test method for recovering and concentrating sulfide ore | 江西浒坑钨业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-112469725-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112295741-A | Test method for recovering and concentrating sulfide ore | 江西浒坑钨业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-4327093-A | TREATING INFECTIONS DISEASES, ANTIBACTERIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-04-27 | — | — | US | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
| US-4268509-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-19 | — | — | US | disclosed |
| EP-0027599-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-29 | — | — | EP | disclosed |
| US-4234724-A | OXADETHIACEPHEMCARBOXYLIC ACIDS | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1980-11-18 | — | — | US | disclosed |
| EP-0010313-A1 | 3,7-Disubstituted-2- or -3-cephem-4-carboxylic acid compounds, pharmaceutical compositions containing them and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
| EP-0007470-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | LMNA 3468/4885GAA 345/4885MAPT 3146/4885 |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | LMNA 3468/4885GAA 345/4885MAPT 3146/4885 |
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | PEPD, SI, NAALAD2 | LMNA 532/4885GAA 56/4885MAPT 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.